Author Interviews, Diabetes, Kidney Disease, NYU, Weight Research / 20.10.2025
NYU Study Finds GLP-1 Medications Associated with Clinically Meaningful Benefit in Dialysis Patients
MedicalResearch.com Interview with:
[caption id="attachment_71025" align="alignleft" width="225"]
Dr. Weintraub[/caption]
Michael A. Weintraub, MD
Clinical Assistant Professor
Department of Medicine
NYU Grossman School of Medicine
MedicalResearch.com: What is the background for this study?
Response: The study addresses a critical knowledge gap in diabetes
management for dialysis patients.
Of the 808,000 people on dialysis in the United States,
approximately 60% have diabetes and would be
eligible for GLP-1 receptor agonists (GLP-1 RAs).
However, these medications have not been well-studied in this population because
dialysis dependence is frequently an exclusion criterion in clinical
trials.
Dr. Weintraub[/caption]
Michael A. Weintraub, MD
Clinical Assistant Professor
Department of Medicine
NYU Grossman School of Medicine
MedicalResearch.com: What is the background for this study?
Response: The study addresses a critical knowledge gap in diabetes
management for dialysis patients.
Of the 808,000 people on dialysis in the United States,
approximately 60% have diabetes and would be
eligible for GLP-1 receptor agonists (GLP-1 RAs).
However, these medications have not been well-studied in this population because
dialysis dependence is frequently an exclusion criterion in clinical
trials.